Fusion Antibodies, pre-clinical antibody discovery and development experts is pleased to announce that it has secured an important new contract with a US based biotechnology company.
This is the second collaboration announcement in less than two months for Fusion Antibodies, which will see the Belfast based CRO receive a minimum of US$1.83 million of fees over the next two years.
This collaborative research and development agreement reinforces Fusion Antibodies’ position as one of the leading providers of early-stage antibody discovery and engineering services and is testament to its rapidly growing service offerings.
Dr Richard Jones, CEO of Fusion Antibodies commented:
“We are delighted to have agreed this important new contract with a key player in the biotech industry. The Agreement has very significant minimum contract value of US$1.83 million.
“Furthermore, we are especially pleased that the project will take place using our RAMPTM platform, highlighting that this technology continues to gain traction in the marketplace.”
Dr Julie Gormley, Senior Commercial Director said:
“This contract is also a further demonstration of Fusion Antibodies expertise and capabilities. Through the utilisation of our own proprietary RAMPTM platform we are offering our client the opportunity to drive the discovery of novel therapeutic antibodies against tough targets, where traditional discovery efforts have previously failed.
“We are thrilled to be working with a team of impassioned scientists to provide essential solutions in relation to the research and development of several pre-determined projects and as we continue to grow and invest in our technologies and team we hope to provide such support to many more clients across the globe as our industry evolves over the next 10 to 20 years.”
James Fair, Chief Financial Officer also commented:
“Under our new CEO, Dr Richard Jones, Fusion Antibodies approach is to grow the business with a strong focus on using the organisation’s strong track record. By showcasing the knowledge and expertise of our exceptional staff, along with our first-rate proprietary platforms, we are in a prime position to continue to win large, long-term contracts such as the one we have announced today. We look forward to delivering on the contract and continuing to collaborate with other such organisations.”